Takeda To Invest $754 M for New Mfg Facility for Plasma-Derived Therapies By
Takeda has announced that it will invest approximately JPY 100 billion ($754 million) to build a new manufacturing facility for plasma-derived therapies in Osaka, Japan. This represents Takeda’s largest investment ever for a manufacturing capacity expansion in Japan. The site is expected to be operational by approximately 2030.
The facility will be a fully integrated plant, comprising teardown, fractionation, purification, filling, and finishing capabilities as well as a cold storage warehouse. The design will be environmentally friendly to support Takeda’s goal of achieving net-zero greenhouse gas emissions related to operations, including for Scopes 1 and 2 emissions, before 2035. Takeda’s existing plasma manufacturing site in Narita, Japan, will continue day-to-day operations until at least the end of the decade, with continued necessary investments for maintenance.